PHATHOM PHARMACEUTICALS, INC. Proceeds from Issuance of Convertible Preferred Stock
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Proceeds from Issuance of Convertible Preferred Stock of $88.32 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2021-03-30
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2019-09-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2018-12-31 was $1.05M.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for fiscal 2019 was $88.32M, a 4548.63% increase from fiscal 2018.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for fiscal 2018 was $1.90M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | $88.32M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $88.32M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $88.32M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $1.90M 10-K · filed 2020-03-19 | ||
| 2018-09-30 | $850.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |